ReviewNeurodegenerative disease management2026
Potential diagnostic markers in Alzheimer's disease: current perspectives and future directions.
Review in Neurodegenerative disease management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bile acids in Alzheimer's disease: a double-edged sword in gut-liver-brain signaling and neurodegeneration.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Analytical Methods for Fluid Biomarkers in Alzheimer's Disease from Discovery to Clinical Implementation.International journal of molecular sciences · 2026Review
- Vascular stiffness predicts plasma markers of neurodegeneration among older African Americans.The journal of prevention of Alzheimer's disease · 2026Observational
- Engineered Protein Modification: A New Paradigm for Enhancing Biosensing Sensitivity and Diagnostic Accuracy.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), the most common form of dementia, remains a leading neurodegenerative disorder that necessitates the development of diagnostic markers. While current cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers facilitate diagnostic accuracy, their invasive and pricey nature limits widespread application. Blood-based biomarkers, such as plasma Aβ42/40 and phosphorylated tau isoforms, are emerging as accessible alternatives. Biomarkers reflecting neurodegeneration (e.g. neurofilament light chain, brain-derived tau) and neuroinflammation (e.g. glial fibrillary acidic protein, TSPO-PET) provide additional insights into disease progression. Novel approaches - including exosomal and Aβ seeds biomarkers, omics techniques, and retinal imaging - further broaden the diagnostic landscape. Despite the promising perspectives, challenges remain in validity and utility. This review highlights recent advances of AD diagnostic markers, evaluates their clinical potential and limitations, and outlines future directions guided by the Geneva five-phase roadmap. The ultimate aim is to facilitate earlier detection and timely intervention of this burdensome disorder.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.